Table of Contents
PPT Slide
Individuals With MCI Develop Clinical AD At A Much Higher Rate Than Normal Elderly
Memory Testing Increases the Prediction Accuracy of Future AD Over Clinical Evaluation Alone
Prevention of AD is Highly Desirable but Prevention Trials with Clinically Normal Individuals are Necessarily Large and Expensive
Far Fewer MCI Subjects Than Normals Are Needed to Demonstrate a 33% Reduction in Conversion Rate to AD
Advantages of MCI/AD Prevention Trials Over Primary Prevention Trials
MCI Trial with Vitamin E and Donepezil
Subject Selection
MCI Trial Endpoints
MCI Trial Participants At Baseline Have Memory Deficits But Are Much Less Impaired than Patients in Standard AD Trials
MCI Study Participants Have Only Subtle Impairment in Function Compared to Mild AD Patients
Hippocampal Volume Correlates with Baseline Memory Performance
Rate of Conversion to AD in MCI Trial at 1 Year Approximates Predicted Rate
MCI Participants Progress at a Slower Annual Rate Than Patients in Standard AD Trials
MCI Trial Participants Generally Decline Slowly While Converters to AD Show More Rapid Decline over 1 Year
Conclusions
Conclusions
Clinical Value of MCI Diagnosis
|